LPL Financial
RLMD icon

LPL Financial’s Relmada Therapeutics RLMD Stock Holding History

LPL Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
+48,571
New +$339K ﹤0.01% 5360
2024
Q4 		– Sell
-13,490
Closed -$43.7K – 5411
2024
Q3 		$43.7K Sell
13,490
-1,938
-13% -$6.28K ﹤0.01% 5014
2024
Q2 		$46.3K Buy
15,428
+2,933
+23% +$10.6K ﹤0.01% 4845
2024
Q1 		$58.1K Sell
12,495
-1,190
-9% -$5.73K ﹤0.01% 4751
2023
Q4 		$56.7K Buy
13,685
+725
+6% +$2.15K ﹤0.01% 4635
2023
Q3 		$38.9K Buy
+12,960
New +$38.5K ﹤0.01% 4545

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LPL Financial's RLMD Position: Q2 2026 in Review

LPL Financial opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 48,571 shares worth $336K. The stake represents ﹤0.01% of the portfolio and ranks #5360 among its holdings. This is a return to the name: LPL Financial previously reported a position in RLMD as recently as Q3 2024.

LPL Financial first reported a position in RLMD in Q3 2023 and has held it in 6 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • LPL Financial held 48,571 shares of Relmada Therapeutics worth $336K as of Q2 2026.
  • Relmada Therapeutics was a new LPL Financial position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #5360 holding.
  • LPL Financial first reported a position in Relmada Therapeutics in Q3 2023 and has held it in 6 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.